Karyopharm Therapeutics (KPTI) to Update on Multiple Myeloma Trajectory; Plans Expansion of Selinexor Phase 2b

August 30, 2016 12:19 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced it will provide an overview of top-line results from its Phase 2b STORM study and the planned development path for selinexor (KPT-330) in multiple myeloma (MM) on Tuesday, September 6, 2016, followed by a conference call on Tuesday, September 6, 2016 at 8:30 a.m., Eastern time. To access the conference call, please dial (855) 437-4406 (US) or (484) 756-4292 (international) at least five minutes prior to the start time and refer to conference ID: 74213103. Accompanying slides will be available under "Events & Presentations" in the "Investor" section of Karyopharm's website, http://www.karyopharm.com, where an audio recording of the call will be available approximately two hours after the event.

Karyopharm today confirmed that, as had been reported on clinicaltrials.gov, it intends to expand its Phase 2b STORM study evaluating the activity of selinexor in multiple myeloma (MM) to include approximately 120 additional patients with penta-refractory MM. Patients with penta-refractory myeloma have previously received two proteasome inhibitors (PIs) (bortezomib (Velcade®) and carfilzomib (Kyprolis®)) and two immunomodulatory agents (IMiDs) (lenalidomide (Revlimid®) and pomalidomide (Pomalyst®)), and their disease is refractory to at least one PI, at least one IMiD and an anti-CD38 monoclonal antibody, such as daratumumab (Darzalex™) or isatuximab, and has progressed following their most recent therapy. Selinexor, the Company’s lead, novel, oral Selective Inhibitor of Nuclear Export / SINE™ compound, is being developed for the treatment of a variety of malignancies, including MM.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment